Rosiglitazone and Adrenocortical Cancer Cell Growth
Author Information
Author(s): Cantini Giulia, Lombardi Adriana, Piscitelli Elisabetta, Poli Giada, Ceni Elisabetta, Marchiani Sara, Ercolino Tonino, Galli Andrea, Serio Mario, Mannelli Massimo, Luconi Michaela
Primary Institution: University of Florence
Hypothesis
Does rosiglitazone inhibit the proliferation of adrenocortical cancer cells by interfering with IGF-IR signaling?
Conclusion
Rosiglitazone inhibits the proliferation of human adrenocortical cancer cells by interfering with key signaling pathways activated by IGF-IR.
Supporting Evidence
- Rosiglitazone reduced cell viability in a dose-dependent manner.
- The IC50 for rosiglitazone was calculated to be 22.48 ± 1.54 μM.
- Both cell lines expressed high levels of IGF-IR, making them responsive to IGF-I.
Takeaway
Rosiglitazone, a diabetes drug, can help stop cancer cells from growing by blocking signals that tell them to multiply.
Methodology
The study used two human adrenocortical carcinoma cell lines (SW13 and H295R) to assess the effects of rosiglitazone on cell proliferation and signaling pathways.
Limitations
The study primarily focuses on in vitro models, which may not fully replicate in vivo conditions.
Participant Demographics
Three normal human adrenal glands, three adrenal carcinomas, and three adenomas were used.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website